Calamos Advisors LLC Boosts Stock Holdings in Masimo Corporation (NASDAQ:MASI)

Calamos Advisors LLC lifted its position in shares of Masimo Corporation (NASDAQ:MASI - Free Report) by 44.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,449 shares of the medical equipment provider's stock after buying an additional 7,169 shares during the period. Calamos Advisors LLC's holdings in Masimo were worth $3,907,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Jones Financial Companies Lllp acquired a new stake in Masimo in the 4th quarter valued at about $27,000. Farther Finance Advisors LLC boosted its position in shares of Masimo by 128.9% in the first quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 116 shares during the period. EverSource Wealth Advisors LLC grew its position in shares of Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 64 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 60 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in Masimo in the fourth quarter valued at about $46,000. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Stock Down 3.1%

MASI traded down $5.12 during mid-day trading on Monday, reaching $162.45. 832,123 shares of the stock were exchanged, compared to its average volume of 640,060. Masimo Corporation has a 1 year low of $101.61 and a 1 year high of $194.88. The stock has a market capitalization of $8.81 billion, a PE ratio of -17.72 and a beta of 1.19. The company has a 50 day moving average price of $161.86 and a two-hundred day moving average price of $166.39. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.62 and a current ratio of 2.17.

Masimo (NASDAQ:MASI - Get Free Report) last announced its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, topping analysts' consensus estimates of $1.24 by $0.12. Masimo had a positive return on equity of 22.56% and a negative net margin of 25.06%. The firm had revenue of $372.00 million for the quarter, compared to the consensus estimate of $367.79 million. During the same quarter in the previous year, the business earned $0.77 EPS. The company's revenue was down 24.5% compared to the same quarter last year. As a group, research analysts anticipate that Masimo Corporation will post 4.1 EPS for the current year.

Insiders Place Their Bets

In other Masimo news, COO Bilal Muhsin sold 10,000 shares of Masimo stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $163.28, for a total value of $1,632,800.00. Following the sale, the chief operating officer owned 24,172 shares of the company's stock, valued at approximately $3,946,804.16. The trade was a 29.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 16.90% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on MASI shares. Wall Street Zen downgraded Masimo from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Piper Sandler reissued an "overweight" rating and set a $200.00 target price (down previously from $215.00) on shares of Masimo in a research report on Wednesday, May 7th. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research report on Thursday, April 10th. Wells Fargo & Company dropped their target price on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Finally, BTIG Research set a $193.00 price target on Masimo and gave the stock a "buy" rating in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $191.60.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.